MCM
SAGE icon

McKinley Capital Management’s Sage Therapeutics SAGE Stock Holding History

McKinley Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-282
Closed -$45K – 272
2019
Q1 		$45K Buy
282
+98
+53% +$14.2K ﹤0.01% 241
2018
Q4 		$18K Sell
184
-219
-54% -$25.1K ﹤0.01% 280
2018
Q3 		$57K Sell
403
-35
-8% -$5.4K ﹤0.01% 280
2018
Q2 		$69K Sell
438
-37
-8% -$5.81K ﹤0.01% 287
2018
Q1 		$76K Buy
+475
New +$80.6K ﹤0.01% 282

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

McKinley Capital Management's SAGE Position: Q2 2019 in Review

McKinley Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 282 shares — an estimated $45K sold.

McKinley Capital Management first reported a position in SAGE in Q1 2018 and held it in 5 quarters. The position peaked at $76K in Q1 2018. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • McKinley Capital Management reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • McKinley Capital Management sold 282 Sage Therapeutics shares in Q2 2019, an estimated $45K.
  • McKinley Capital Management first reported a position in Sage Therapeutics in Q1 2018 and held it in 5 quarters.
  • McKinley Capital Management's Sage Therapeutics position peaked at $76K in Q1 2018.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on McKinley Capital Management's 13F filing for Q2 2019, filed 7 Aug 2019.